Literature DB >> 24057324

Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.

Ayal A Aizer1, Marek Ancukiewicz, Paul L Nguyen, Shannon M Macdonald, Torunn I Yock, Nancy J Tarbell, Helen A Shih, Jay S Loeffler, Kevin S Oh.   

Abstract

Patients with World Health Organization (WHO) grade II supratentorial ependymomas are commonly observed after gross total resection (GTR), although supporting data are limited. We sought to characterize the natural history of such tumors. We used the Surveillance, Epidemiology, and End Results program to identify 112 patients ages 0-77 diagnosed with WHO grade II ependymomas between 1988 and 2007, of whom 63 (56 %) and 49 (44 %) had supratentorial and infratentorial primaries, respectively. Inclusion criteria were strict to ensure patient homogeneity. Of 33 patients with supratentorial tumors after GTR, 18 (55 %) received adjuvant radiation therapy and 15 (45 %) did not. Ependymoma-specific mortality (ESM) was the primary endpoint. With a median follow up of 4.5 years, only 1 of 33 patients with supratentorial ependymoma died of their disease after GTR; the 5-year estimate of ESM in this population was 3.3 % (95 % CI 0.2-14.8 %). Among patients with infratentorial ependymomas after GTR, the 5-year estimate of ESM was 8.7 % (95 % CI 1.4-24.6 %). In patients with subtotally resected tumors, 5-year estimates of ESM in patients with supratentorial and infratentorial primaries were 20.1 % (95 % CI 8.0-36.2 %) and 12.3 % (95 % CI 2.9-28.8 %), respectively. Among the whole cohort, on both univariable and multivariable regression, extent of resection was predictive of ESM, while tumor location and use of radiation were not. After GTR, patients with WHO grade II supratentorial ependymomas have a very favorable natural history with low associated cancer-specific mortality. Observation, with radiation reserved as a salvage option, may be a reasonable postoperative strategy in this population.

Entities:  

Mesh:

Year:  2013        PMID: 24057324     DOI: 10.1007/s11060-013-1237-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Is gross-total resection sufficient treatment for posterior fossa ependymomas?

Authors:  Leland Rogers; Jeanette Pueschel; Robert Spetzler; William Shapiro; Stephen Coons; Terry Thomas; Burton Speiser
Journal:  J Neurosurg       Date:  2005-04       Impact factor: 5.115

2.  Early stage breast cancer treatments for younger Medicare beneficiaries with different disabilities.

Authors:  Lisa I Iezzoni; Long H Ngo; Donglin Li; Richard G Roetzheim; Reed E Drews; Ellen P McCarthy
Journal:  Health Serv Res       Date:  2008-05-12       Impact factor: 3.402

3.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

5.  Postoperative radiation therapy for grade II and III intracranial ependymoma.

Authors:  David B Mansur; Arie Perry; Veena Rajaram; Jeff M Michalski; T S Park; Jeffrey R Leonard; Lori Luchtman-Jones; Keith M Rich; Perry W Grigsby; Mary Ann Lockett; Sasha H Wahab; Joseph R Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

6.  Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma.

Authors:  W H St Clair; J A Adams; M Bues; B C Fullerton; Sean La Shell; H M Kooy; J S Loeffler; N J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

7.  Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study.

Authors:  Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin
Journal:  Lancet Oncol       Date:  2007-08       Impact factor: 41.316

8.  Predicting change in academic abilities after conformal radiation therapy for localized ependymoma.

Authors:  Heather M Conklin; Chenghong Li; Xiaoping Xiong; Robert J Ogg; Thomas E Merchant
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

9.  Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons.

Authors:  Shannon M MacDonald; Sairos Safai; Alexei Trofimov; John Wolfgang; Barbara Fullerton; Beow Y Yeap; Thomas Bortfeld; Nancy J Tarbell; Torunn Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-05       Impact factor: 7.038

10.  Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study.

Authors:  A E Evans; J R Anderson; I B Lefkowitz-Boudreaux; J L Finlay
Journal:  Med Pediatr Oncol       Date:  1996-07
View more
  8 in total

1.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Authors:  Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-08-13       Impact factor: 12.300

Review 2.  Recent Advances in the Classification and Treatment of Ependymomas.

Authors:  Heather Leeper; Michelle M Felicella; Tobias Walbert
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

Review 3.  Advances in Management of Pediatric Ependymomas.

Authors:  Frank Y Lin; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2015-10       Impact factor: 5.075

4.  EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell.

Authors:  Phylip Chen; Nathan Rossi; Samuel Priddy; Christopher R Pierson; Adam W Studebaker; Robert A Johnson
Journal:  Sci Rep       Date:  2015-03-24       Impact factor: 4.379

5.  The role of postoperative radiotherapy in pediatric patients with grade II intracranial ependymomas: a population-based, propensity score-matched study.

Authors:  Xiangyang Deng; Dongdong Lin; Lisheng Yu; Xingxing Xu; Nu Zhang; Hui Zhou; Hansong Sheng; Bo Yin; Fengchun Lin; Shangyu Xu; Dandong Li; Junhao Fang; Xiangqi Lu; Jian Lin
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

6.  Do We Need Radiotherapy in Grade II Ependymoma?

Authors:  Aleksandra Napieralska; Wojciech Majewski; Leszek Miszczyk
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

Review 7.  Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era.

Authors:  Tae-Young Jung; Shin Jung; Hoon Kook; Hee-Jo Baek
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

Review 8.  Molecular Classification and Therapeutic Targets in Ependymoma.

Authors:  Thomas Larrew; Brian Fabian Saway; Stephen R Lowe; Adriana Olar
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.